Skip to content

Evarmed: what changed

BE 0801.396.875NACE 21.100, Manufacture of basic pharmaceutical products and pharmaceutical preparationsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
-€23,066
2024 · -€49,202+€26,136
Equity
-€62,268
2024 · -€39,202-€23,066
Cash
€65
2024 · €5,839-€5,774
Balance sheet total
€51,346
2024 · €44,184+€7,162

Largest movements

2024 to 2025
Assets
  • Intangible fixed assets +€14,175

    up €14,175 (+40.0%), from €35,458 to €49,633

  • Cash -€5,774

    down €5,774 (-98.9%), from €5,839 to €65

    mainly Investment in fixed assets (net) (-€38,330) and Net result for the year (-€23,066)

  • Receivables within one year -€784

    down €784 (-51.3%), from €1,528 to €744

Equity and liabilities
  • Other debts +€26,118

    up €26,118 (+38.0%), from €68,800 to €94,917

  • Profit (loss) carried forward -€23,066

    down €23,066 (-46.9%), from -€49,202 to -€72,268

  • Accrued charges and deferred income +€5,138

    up €5,138 (+38.5%), from €13,352 to €18,490

  • Trade debts -€1,028

    down €1,028 (-83.3%), from €1,234 to €206

Income statement
  • Gross operating margin +€32,392

    up €32,392, from -€31,043 to €1,349

  • Depreciation +€6,470

    up €6,470 (+36.6%), from €17,686 to €24,155

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 -€49,202
Gross operating margin +€32,392
Depreciation -€6,470
Other operating charges +€127
Financial income -€16
Financial charges +€103
Result 2025 -€23,066
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€32,556
Investment -€38,330
Financing €0
Cash 2024 €5,839
Net result for the year -€23,066
Depreciation +€24,155
Receivables within one year +€784
Deferred charges and accrued income +€454
Trade debts -€1,028
Other debts +€26,118
Accrued charges and deferred income +€5,138
Investment in fixed assets (net) -€38,330
Cash 2025 €65
brings cash intakes cash out
Every line side by side 30 lines
Line Code 2024 2025 Change %
Total assets 20/58 €44,184 €51,346 +€7,162 +16.2%
Fixed assets 21/28 €36,358 €50,533 +€14,175 +39.0%
Intangible fixed assets 21 €35,458 €49,633 +€14,175 +40.0%
Financial fixed assets 28 €900 €900 = 0.0%
Current assets 29/58 €7,826 €813 -€7,013 -89.6%
Amounts receivable within one year 40/41 €1,528 €744 -€784 -51.3%
Other amounts receivable 41 €1,528 €744 -€784 -51.3%
Cash at bank and in hand 54/58 €5,839 €65 -€5,774 -98.9%
Deferred charges and accrued income 490/1 €459 €4 -€454 -99.1%
Total equity and liabilities 10/49 €44,184 €51,346 +€7,162 +16.2%
Equity 10/15 -€39,202 -€62,268 -€23,066 -58.8%
Contributions 10/11 €10,000 €10,000 = 0.0%
Profit (loss) carried forward 14 -€49,202 -€72,268 -€23,066 -46.9%
Amounts payable 17/49 €83,386 €113,613 +€30,228 +36.3%
Amounts payable within one year 42/48 €70,033 €95,123 +€25,090 +35.8%
Trade debts 44 €1,234 €206 -€1,028 -83.3%
Suppliers 440/4 €1,234 €206 -€1,028 -83.3%
Other amounts payable 47/48 €68,800 €94,917 +€26,118 +38.0%
Accrued charges and deferred income 492/3 €13,352 €18,490 +€5,138 +38.5%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €17,686 €24,155 +€6,470 +36.6%
Other operating charges 640/8 €193 €66 -€127 -66.0%
Gross operating margin 9900 -€31,043 €1,349 +€32,392
Operating profit (loss) 9901 -€48,921 -€22,872 +€26,049 +53.2%
Financial income 75/76B €17 €1 -€16 -94.4%
Recurring financial income 75 €17 €1 -€16 -94.4%
Financial charges 65/66B €298 €195 -€103 -34.6%
Recurring financial charges 65 €298 €195 -€103 -34.6%
Profit (loss) for the period before taxes 9903 -€49,202 -€23,066 +€26,136 +53.1%
Profit (loss) for the period 9904 -€49,202 -€23,066 +€26,136 +53.1%
Profit (loss) for the period to be appropriated 9905 -€49,202 -€23,066 +€26,136 +53.1%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.

Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.

Adjusted equity -€111,900

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
-€62,268
Intangible fixed assets (21)
-€49,633
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
-€111,900

Capitalised earnings

net result for the year (9904)
2025
-€23,066
2024
-€49,202
Average result
-€36,134
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
not meaningful, as the average result is zero or negative

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 16 November 2026 via checked.be.